Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Accumulated Expenses (2016 - 2026)

Angiodynamics' Accumulated Expenses history spans 16 years, with the latest figure at $32.3 million for Q1 2026.

  • For Q1 2026, Accumulated Expenses fell 12.57% year-over-year to $32.3 million; the TTM value through Feb 2026 reached $32.3 million, down 12.57%, while the annual FY2025 figure was $35.5 million, 13.58% down from the prior year.
  • Accumulated Expenses reached $32.3 million in Q1 2026 per ANGO's latest filing, up from $29.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $41.1 million in Q2 2024 to a low of $21.8 million in Q1 2023.
  • Average Accumulated Expenses over 5 years is $30.8 million, with a median of $29.9 million recorded in 2025.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 54.41% in 2024, then decreased 25.22% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $26.5 million in 2022, then grew by 10.19% to $29.2 million in 2023, then surged by 36.54% to $39.9 million in 2024, then fell by 25.22% to $29.9 million in 2025, then rose by 8.21% to $32.3 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Accumulated Expenses are $32.3 million (Q1 2026), $29.9 million (Q4 2025), and $27.7 million (Q3 2025).